# Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India

> **NCT00923702** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Partha Basu** · enrollment: 22729 (actual)

## Conditions studied

- Cervical Cancer
- Cervical Precancerous Lesions

## Interventions

- **BIOLOGICAL:** Prophylactic quadrivalent HPV vaccine Merck (Gardasil®)

## Key facts

- **NCT ID:** NCT00923702
- **Lead sponsor:** Partha Basu
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2009-09
- **Primary completion:** 2017-01
- **Final completion:** 2026-07
- **Target enrollment:** 22729 (ACTUAL)
- **Last updated:** 2023-09-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00923702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00923702, "Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00923702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*